Department of Pathology, Kyungpook National University Chilgok Hospital, Kyungpook National University School of Medicine, Daegu, Republic of Korea.
Department of Neurosurgery, Brain Tumor Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Anticancer Res. 2022 Jan;42(1):335-341. doi: 10.21873/anticanres.15490.
The methylation status of the O-methylguanine-DNA methyltransferase (MGMT) promoter plays a key role in response to temozolomide chemotherapy and disease prognosis in patients with wild-type isocitrate dehydrogenase (IDH) glioblastoma (GBM).
The MGMT promoter methylation status and its association with clinicopathological parameters were retrospectively analysed in a cohort of 316 patients with GBM with wild-type IDH.
MGMT methylation was significantly associated with ATRX chromatin remodeler (ATRX) loss and completion of the standard Stupp protocol. The median durations of overall and progression-free survival for the unmethylated, low-methylated (10-39%), and hypermethylated (≥40%) groups were 15, 23, and 30 months and 11, 18, and 21 months, respectively. However, the improvement in the survival of the hypermethylated group was not statistically significant.
We suggest a possible association between MGMT methylation status and ATRX mutations in GBM with wild-type IDH.
O-甲基鸟嘌呤-DNA 甲基转移酶（MGMT）启动子的甲基化状态在野生型异柠檬酸脱氢酶（IDH）胶质母细胞瘤（GBM）患者对替莫唑胺化疗的反应和疾病预后中起着关键作用。
对 316 例 IDH 野生型 GBM 患者的队列进行了 MGMT 启动子甲基化状态及其与临床病理参数关系的回顾性分析。
MGMT 甲基化与 ATRX 染色质重塑酶（ATRX）缺失和标准 Stupp 方案的完成显著相关。未甲基化、低甲基化（10-39%）和高甲基化（≥40%）组的总生存和无进展生存中位数分别为 15、23 和 30 个月和 11、18 和 21 个月。然而，高甲基化组的生存改善无统计学意义。
我们建议在 IDH 野生型 GBM 中，MGMT 甲基化状态与 ATRX 突变之间可能存在关联。
